Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC

Prior treatment

• Participate in other clinical trials at present or within four weeks before enrollment;
• Simultaneous treatment with other anti-cancer drugs (including anti-cancer traditional Chinese medicine);
• Known or suspected allergic to chemotherapy drugs; According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.

Other illness

• History of malignant tumors in other parts;
• Serious comorbidities: very high-risk hypertension, severe pulmonary function impairment, massive myocardial infarction, cardiac function ≥ grade II, mental history and severe diabetes;
• During the active period of infectious diseases;
• Cases with perforation tendency;
• Have a history of organ transplantation.

Other

• Duplicate carcinoma of the esophagus;
• Pregnant or lactating patients;
• Fertility but not using contraceptive measures;
• After esophageal stent placement;
• Widespread metastases throughout the body, including lung, liver, bone, and intracranial metastases;

• Age 18-70 years old, not limited to male or female; at least able to take liquid diet;
• Esophageal squamous cell carcinoma proved by histopathology;
• Esophageal squamous cell carcinoma that is inoperable or refuses surgery,
• According to the 2017 8th edition of AJCC esophageal cancer new staging criteria, the tumor is T2N0M0-TxNxM0 stage;
• ECOG 0-1; life expectancy \> 6 months;
• No chemotherapy was used before selection;
• No history of radiotherapy;
• No surgical treatment;
• No serious allergic history;
• Hemoglobin 100 g/L, WBC3.5109/L, neutrophils 1.5109, platelets 100109/L; CR1.5 upper limit of normal, TB2.5 upper limit of normal, AST and ALT2.5 upper normal limit, AKP2.5 upper normal limit ; Be able to understand the research and have signed the informed consent;